On October 21, 2025, Nexalin Technology, Inc. announced that three peer‑reviewed studies have been published showing that its 15‑mA Gen‑2 DIFS technology improves cognition and brain network activity in Alzheimer’s disease patients. The first study, TRANSFORM‑AD, randomized 46 patients to 30 one‑hour DIFS sessions over 15 days and reported significant improvements in MMSE and MoCA scores, enhanced hippocampal theta‑gamma coupling, and increased low‑frequency fluctuations on fMRI.
The second study, published in the Journal of Alzheimer’s Disease, used resting‑state fMRI to demonstrate increased fractional amplitude of low‑frequency fluctuations (fALFF) and regional homogeneity (ReHo) in prefrontal and memory‑related regions, indicating restored neuronal synchronization. The third study, appearing in Radiology in June 2025, showed that DIFS improved cognition while enhancing connectivity between the hippocampus and cortical regions, including the middle cingulate and middle frontal gyri, and produced network‑level gains across the default mode and frontoparietal systems.
These converging data support Nexalin’s claim that its 15‑mA Gen‑2 device can restore brain networks and improve cognitive function, positioning the company for regulatory advancement. The global Alzheimer’s market is projected to exceed $20 billion annually, and Nexalin’s technology offers a drug‑free, lower‑cost alternative. The Gen‑2 15‑mA device has already received regulatory approval in China, Brazil, and Oman, underscoring its commercial readiness in key international markets.
CEO Mark White said the studies confirm the mechanism of action and strengthen the company’s regulatory strategy, while Chief Medical Officer David Owens added that the data provide a holistic picture of how DIFS may counteract the disruptions that drive cognitive decline in Alzheimer’s disease. The press release was issued via GlobeNewswire, highlighting the company’s commitment to transparent communication of its scientific progress.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.